X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced its plans to report second quarter 2024 financial results and provide corporate updates on August 8, 2024. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.
Investors and interested parties can access the conference call by dialing 1-800-225-9448 (US) or 1-203-518-9708 (international) with the conference ID: X4PHARMA. A live webcast will also be available through the investor relations section of X4 Pharmaceuticals' website. Following the call, a webcast replay will be accessible on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
On the day this news was published, XFOR declined 2.92%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the second quarter ended June 30, 2024 and provide corporate updates on Thursday, August 8, 2024.
The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will X4 Pharmaceuticals (XFOR) report its Q2 2024 financial results?
How can investors access X4 Pharmaceuticals' (XFOR) Q2 2024 earnings call?
What time is X4 Pharmaceuticals' (XFOR) Q2 2024 earnings call scheduled for?
Where can I find the replay of X4 Pharmaceuticals' (XFOR) Q2 2024 earnings call?
